- CSR Summary Not Yet Available
- NCT00367237
- Primary Citation Trial has yet to be published
- Data Specification Not Yet Availabe
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameInfliximabProduct NameREMICADE®Therapeutic AreaImmune System DiseasesEnrollment115% Female45.5%% WhiteN/A
Product ClassAntirheumatic Agents - Biologic Response ModifiersSponsor Protocol NumberP04422Data PartnerJohnson & JohnsonCondition StudiedArthritis, PsoriaticMean/Median Age (Years)41.2
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Clinical Study Report Available